Filana Therapeutics (FLNA) reported second-quarter 2026 financial results and said it continues to engage with the FDA regarding the clinical hold on its proof-of-concept trial in TSC-related epilepsy.
The company reported cash and cash equivalents of $82.7 million at June 30, 2026, compared with $95.5 million at Dec. 31, 2025, and said it has no debt.
- Second-quarter net loss was $8.6 million, or $0.18 per share, compared with a net loss of $44.2 million, or $0.92 per share, in the prior-year period.
- R&D expenses were $3.3 million, down from $5.1 million a year earlier.
- G&A expenses were $6.1 million, down from $40.3 million a year earlier.
- Net cash used in operations was $12.7 million during the first half of 2026.
- The company paid $31.25 million into escrow on July 23, 2026, related to a potential securities litigation settlement recorded in 2025.
- Filana estimated year-end 2026 unrestricted cash of $36 million to $40 million.
EARLY ACCESS
Receive SAVA Data Alerts
Real-time alerts on filings, insider trades, and market signals — before everyone else.
Get Alerts →
